News List

Piramal Pharma Solutions names John Fowler as CEO


As Chief Operating Officer, John Fowler will be responsible for Piramal Pharma Solutions’ Global Operations and R&D

BY TEAM ABLE

Piramal Pharma Solutions (PPS), part of Piramal Enterprises Limited, has appointed John Fowler as its Chief Operating Officer.
PPS is a leader in Integrated Contract Development and Manufacturing, with a global network of 12 development and manufacturing facilities across North America, Europe and Asia.

PPS offers a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies and Commercial supply of APIs and Finished dosage forms.

As Chief Operating Officer, John will be responsible for Global Operations and Research & development (R&D), and will play a lead role in ensuring that our customers consistently experience differentiated and excellent levels of service.
Commenting on his appointment, John Fowler said, \"I was very impressed with the range of capabilities and the breadth of expertise that resides across PPS, and its global footprint. With external partnerships now becoming an integral part of how pharmaceutical firms and biotechs do business, I firmly believe that leading Contract Development and Manufacturing Organizations (CDMO\'s), like PPS, are at an inflexion point in their growth curve.

PPS is a global leader with a strong customer-centric culture, a strong focus on innovation, a robust balance sheet, a commitment towards investment, and finally, a global talent pool that combines speed with quality and delivery. As our customers seek dependable partners that can offer seamless, integrated solutions, from Discovery through Commercialization, from Drug Substance to Drug Product, I look forward to positioning PPS to deliver on these needs, and building long term, sustainable and strategic partnerships.\"

Most recently, John served as the Divisional CEO of the Global Fine Chemicals business at Johnson Matthey (JM), with responsibility for JM\'s Services (Custom API Development, Manufacturing, Catalyst & Chiral Technologies), and Products (Generics Development and Manufacturing) portfolio. Before leading JM\'s Fine Chemical Division, John held senior leadership roles in several business verticals at JM, including Pharmaceutical Materials and Services, Environmental Catalysts and Technologies, among others. John has a Chemical Engineering degree from Bucknell University and an MBA from St. Joseph University.